Sharemaestro Newsreel

Lantheus (LNTH) to Release Earnings on Wednesday

HC Wainwright Analysts Decrease Earnings Estimates for CRDL

Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Evolus (EOLS) Projected to Post Quarterly Earnings on Wednesday

Cumberland Pharmaceuticals (CPIX.US) will release its earnings report after the market closes on August 4.

Perrigo (PRGO) Projected to Release Quarterly Earnings on Wednesday

Emergent Biosolutions (EBS) Projected to Post Earnings on Wednesday

Anika Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ANIK) 2026-07-29

Aurora Cannabis (ACB) to Post Quarterly Earnings on Wednesday

Phibro Animal Health Corporation (NASDAQ:PAHC) Announces $0.12 Quarterly Dividend

BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday

Wedbush Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $98.00

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD

Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for …

Tilray Brands, Inc. Stock 12‑Month Price Target Cut to $8.52, Implies 111% Upside

Tilray Brands, Inc.'s average 12-month price target has been cut to $8.52 from $8.62, according to estimates from 6 analysts. This updated target implies a potential upside of approximately 111% from its July 28 closing price. The consensus rating for TLRY remains "Buy," with …

Indivior PLC (INDV) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Indivior PLC (INDV), highlighting its current risk score of 6.43, ranking 53 out of 155 in the Pharmaceuticals industry. The company's beta of 1.18 suggests it tends to outperform during market uptrends but underperform during downtrends. The …

Bausch Health Companies Inc (BHC) Valuation: PE, PB & Fair Value Analysis

Bausch Health Companies Inc (BHC) has a current valuation score of 9.34, ranking 27th out of 155 companies in the Pharmaceuticals industry. The company's P/E ratio is -1.40, which is significantly below its recent high and above its recent low. However, relevant data for …

TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA

This article provides a revenue breakdown for TherapeuticsMD, Inc. (SWB:29TA), highlighting that the greatest contribution to its revenue comes from the United States. The company reported €1.53 million from the U.S. last year, an increase from €1.08 million the year prior. The data is …

Supernus Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Supernus Pharmaceuticals (NASDAQ: SUPN) had 793 employees as of March 2026, representing a 25.8% decline from 2023. The company is actively hiring, with 105 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, …

Evotec SE (EVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Evotec SE (EVO), focusing on its current price momentum, support and resistance levels, and key indicators like MACD, RSI, and Moving Averages. The stock's price momentum score is 5.21, and it is trading between a resistance of …

Tilray Brands 4Q Loss/Shr 43c >TLRY

Tilray Brands reported a fourth-quarter loss per share of 43 cents. This financial update indicates the company's performance for the recent quarter.

Tilray Brands Inc reports results for the quarter ended May 31 - Earnings Summary

Tilray Brands Inc has released its earnings summary for the quarter that concluded on May 31. The report contains the financial results for the company during this period. The full article provides detailed information on their performance.

Sonoma Pharmaceuticals (Nasdaq: SNOA) 2026 pay, board and auditor votes

Sonoma Pharmaceuticals (SNOA) has issued its definitive proxy statement for the 2026 Annual Meeting, scheduled for September 16, 2026. Shareholders will vote on the re-election of Class III director Jerry McLaughlin, an advisory approval of executive compensation for fiscal year 2026, and the ratification …

Dr. Reddy’s Laboratories (NYSE: RDY) details Q1 impact from semaglutide

Dr. Reddy's Laboratories reported a 5.6% year-on-year decline in Q1 FY27 consolidated revenues, totaling ₹8,071 crores, primarily due to lower lenalidomide sales and a ₹240 crore provision for semaglutide API issues. Despite this, the base business, excluding lenalidomide, showed healthy double-digit growth across key …

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …

Lifecore Biomedical Inc (LFCR) Financial Health: Profitability & Balance Sheet Analysis

Lifecore Biomedical Inc (LFCR) currently holds a weak financial score of 6.79 out of 10, ranking 134th in the Pharmaceuticals industry. While its operating efficiency is high, the company reported a year-over-year revenue decrease of 6.12% and a net profit decrease of 1.82% in …

Emergent BioSolutions Inc (EBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Emergent BioSolutions Inc (EBS), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that EBS has a price momentum score of 3.62, trading between a resistance of 8.22 and support …

Cumberland Pharmaceuticals Inc (CPIX) Financial Health: Profitability & Balance Sheet Analysis

Cumberland Pharmaceuticals Inc (CPIX) has a financial score of 7.53, ranking 110 out of 155 in the pharmaceuticals industry, indicating stable financial status and high operating efficiency. Despite this, its latest quarterly revenue decreased by 22.04% year-over-year, and net profit saw a significant 361.69% …

Viatris Number of Employees 2026 | Employee Count & Headcount Data

Viatris, Inc. (NASDAQ: VTRS) reported approximately 29,935 global employees as of March 2026, marking a 3.8% decline from 2023. The company is actively hiring with 474 open job postings in 2026, a 10.7% increase from 2025. Viatris's workforce is primarily located in India (43.1%), …

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

(RTTNews) - Today's top biotech gainers include Trinity Biotech, which recently completed reverse split; OPKO Health, driven by its second-quarter financial results and continued pipeline progress; Kiniksa Pharma, after raising its revenue outlook on strong commercial momentum; and MapLight Therapeutics, which staged a sharp …

Neurocrine Biosciences, Inc. Revenue Breakdown – BX:NB3

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Emergent BioSolutions | SCHEDULE 13G/A: Others

This article is a SCHEDULE 13G/A filing related to Emergent BioSolutions. It indicates an amendment to a previous filing, typically involving changes in beneficial ownership of the company's stock by a significant investor.

Bausch Health Companies Inc (BHC) Risk Assessment: Volatility, Financial Risk & Investment Risk

Bausch Health Companies Inc (BHC) has a current risk assessment score of 6.07, ranking 59 out of 155 in the Pharmaceuticals industry. The company's beta value of 0.42 indicates it may underperform during bull markets but experience smaller declines during bear markets. The report …

Cronos Group Inc (CRON) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cronos Group Inc (CRON), focusing on its price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy, sell, or neutral signals. The analysis suggests CRON …

KMDA|Kamada Ltd|Price:7.070|Chg%:+0.080

This article provides a detailed stock analysis for Kamada Ltd (KMDA), highlighting its current market trends, financial performance, and analyst ratings. Based on three analysts, the stock has a "Buy" rating with a target price of $13.00, representing an 84.14% upside. While Kamada Ltd …